Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026

Zymeworks (Nasdaq: ZYME) announced it will report its second quarter 2026 financial results after market close on August 6, 2026.

Rhea-AI Summary

Zymeworks (Nasdaq: ZYME) announced it will report its second quarter 2026 financial results after market close on August 6, 2026. The company also noted that, in light of its previously announced proposed acquisition of Theravance Biopharma, it has chosen not to host a second quarter earnings conference call following the release. Zymeworks stated that it expects to provide a further update after the anticipated closing of the proposed Theravance Biopharma acquisition, at which time it plans to offer greater visibility into the combined business and its strategic priorities.

Argus Jul 16 session 1 alert

-1.91% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – ZYME

-3.1% Trough Tracked

$1.81B Market Cap

In the Jul 16 session, ZYME declined 1.91%, reflecting a mild negative market reaction. Argus tracked a trough of -3.1% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Viewed alongside the recent Theravance acquisition announcement, which produced only a -0.21% next-d...

Analysis

Viewed alongside the recent Theravance acquisition announcement, which produced only a -0.21% next-day move, this earnings-date notice fits a pattern of measured trading around Zymeworks news. With short interest flagged as low, investors may focus on closing progress and upcoming Q2 details.

Historical Context

5 past events · Latest: Jun 29

5 events

1. Jun 29

   Theravance acquisition deal

   24h Move

   -0.2%

   Announced all-cash Theravance acquisition adding YUPELRI cash flows and tax assets.

2. Jun 18

   Discovery collaboration

   24h Move

   -0.6%

   Cryo-EM partnership with Gandeeva to support antibody drug discovery and optimization.

3. Jun 14

   Phase 1 clinical data

   24h Move

   +1.7%

   Reported encouraging Phase 1 ZW191 efficacy data in ovarian and endometrial cancers.

4. May 14

   Share repurchase program

   24h Move

   -0.1%

   Authorized new 2026 buyback program to repurchase up to $125 million of stock.

5. May 13

   Investor conferences

   24h Move

   +2.8%

   Announced participation in several oncology and healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.

In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, sharing greater visibility into the combined business and its strategic priorities.

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks’ asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Vice President, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Vice President, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Zymeworks (ZYME) report its second quarter 2026 financial results?

Zymeworks plans to report its second quarter 2026 financial results after market close on August 6, 2026. According to Zymeworks, this timing will provide investors with its latest quarterly financial information on that date.

Will Zymeworks (ZYME) hold an earnings call for Q2 2026 results?

Zymeworks has elected not to host a second quarter 2026 earnings conference call. According to Zymeworks, this decision is related to its previously announced proposed acquisition of Theravance Biopharma and the expected update after closing.

How is the proposed Theravance Biopharma acquisition affecting Zymeworks' Q2 2026 communications?

The proposed Theravance Biopharma acquisition led Zymeworks to skip its usual Q2 2026 earnings call. According to Zymeworks, it plans to provide an update after the expected closing, with more detail on the combined business.

What update does Zymeworks (ZYME) plan to provide after the Theravance Biopharma acquisition closes?

Zymeworks expects to share greater visibility into the combined business and its strategic priorities after the proposed acquisition closes. According to Zymeworks, this future update will follow the expected closing of the Theravance Biopharma transaction.

Why did Zymeworks (ZYME) cancel its usual Q2 2026 earnings conference call?

Zymeworks chose not to host a Q2 2026 earnings call due to its proposed acquisition of Theravance Biopharma. According to Zymeworks, it will instead provide a broader strategic update after the expected closing of the deal.